Amyris, Inc. (AMRS)
| Market Cap | 3.84B |
| Revenue (ttm) | 133.93M |
| Net Income (ttm) | -352.02M |
| Shares Out | 227.27M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $15.26 |
| Previous Close | $14.65 |
| Change ($) | 0.61 |
| Change (%) | 4.16% |
| Day's Open | 15.62 |
| Day's Range | 14.56 - 16.06 |
| Day's Volume | 2,711,554 |
| 52-Week Range | 1.40 - 18.57 |
Even with the market at historic highs, there are still plenty of young growth stocks that have their whole future ahead of them. The post 7 A-Rated Growth Stocks To Buy For Today And Tomorrow...
These are the marijuana stocks with the best value, fastest growth, and most momentum for February 2021.
Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Grow...
EMERYVILLE, Calif., Jan. 22, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer bran...
These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for February.
Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.
Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.
EMERYVILLE, Calif., Dec. 28, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer bran...
Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.
These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for January.
Amyris (AMRS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
EMERYVILLE, Calif., Dec. 21, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer bran...
Amyris has multiple major transactions around the corner. The political and market environment favor the company greatly.
EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brand...
These are the marijuana stocks with the best value, fastest growth, and most momentum for December.
These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for November.
Amyris, Inc. (AMRS) CEO John Melo on Q3 2020 Results - Earnings Call Transcript
EMERYVILLE, Calif., Oct. 30, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a t...
BENSALEM, Pa.--(BUSINESS WIRE)---- $AMRS #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $AMRS #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors
EMERYVILLE, Calif., Oct. 23, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a t...
SEATTLE, Oct. 20, 2020 /PRNewswire/ -- Arzeda, the Protein Design Company™, today announced that the company has entered into a joint development agreement with Amyris that leverages the compl...
LOS ANGELES--(BUSINESS WIRE)---- $AMRS #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Amyris, Inc (“Amyris” or the “Company”...
Amyris' engineered yeast strains and advanced fermentation can produce an unlimited number of new products for billion-dollar markets.
Amyris bolsters balance sheet, shifting focus to cash flow, 40-50% revenue growth and earnings (we estimate $0.72 EPS in 2024).
Amyris (NASDAQ: AMRS) shares were trading higher Tuesday after the company announced its Reb M Neutral Sweetener has received approval for use in food by Health Canada.
EMERYVILLE, Calif., Sept. 14, 2020 /PRNewswire/ -- Amyris, Inc.
The company has responded to a $881 million lawsuit brought against it yesterday.
Biotech firm Amyris Inc. (NASDAQ: AMRS) is clapping back at allegations made by Lavvan Inc.
EMERYVILLE, Calif., Sept. 11, 2020 /PRNewswire/ -- Amyris, Inc.
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- LAVVAN, Inc.
These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential ap...
EMERYVILLE, Calif., Sept. 8, 2020 /PRNewswire/ -- Amyris, Inc.
These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and best performance for September.
Unlocking the true value of the company's consumer portfolio might require a big, bold decision.
EMERYVILLE, Calif., Aug. 14, 2020 /PRNewswire/ -- Amyris, Inc.
A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.
Amyris, Inc. (AMRS) CEO John Melo on Q2 2020 Results - Earnings Call Transcript
These are the marijuana stocks on the nasdaq stocks with the best value, fastest growth, and best performance for August.
NEW YORK, July 29, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
NEW YORK, July 28, 2020 /PRNewswire/ -- URGENT: SHAREHOLDER VOTE AUGUST 14, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of d...
The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.
Amyris (NASDAQ: AMRS) shares are trading higher on Monday after the company signed a binding term sheet for a planned COVID-19 RNA vaccine technology program with the Infectious Disease Resear...
EMERYVILLE, Calif., July 27, 2020 /PRNewswire/ -- Amyris, Inc.
Smaller and speculative marijuana stocks took a beating following the initial coronavirus strike. However, they could also generate massive profitability for the risk-tolerant speculator.
LOS ANGELES--(BUSINESS WIRE)---- $AMRS #AMRS--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amyris, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $AMRS #AMRS--INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims Against Amyris, Inc.
Markets are down today, pretty much from the get-go. As investors become increasingly concerned with the worsening coronavirus cases, it's become clear that a sell-off is imminent.
Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.
About AMRS
Amyris, a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette... [Read more...]
| Industry Specialty Chemicals | IPO Date Sep 28, 2010 |
| CEO John Melo | Employees 561 |
| Stock Exchange NASDAQ | Ticker Symbol AMRS |
Financial Performance
In 2019, Amyris's revenue was $152.56 million, an increase of 139.85% compared to the previous year's $63.60 million. Losses were -$242.77 million, 5.44% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Amyris stock is "Strong Buy." The 12-month stock price forecast is 12.00, which is a decrease of -21.36% from the latest price.